Conbercept is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Conbercept’s likelihood of approval (LoA) and phase transition for Retinoblastoma took place on 30 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Conbercept Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Conbercept (Langmu) is a recombinant fusion protein composed of the second Ig domain of VEGFR1 and the third and fourth Ig domains of VEGFR2 to the constant region (Fc) of human IgG1. It is formulated as ophthalmic Injection meant for an Intravitreal route of administration. Conbercept is indicated for the treatment of wet age-related macular degeneration (AMD).
It is under development for the treatment of retinoblastoma, diabetic macular edema, neovascular age-related macular degeneration and macular edema caused by central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Chengdu Kanghong Pharmaceuticals Group (Kanghong Pharmaceuticals) focuses on the development, manufacturing and marketing of Chinese medicines, chemical drugs, and biological products. It offers products for the treatment of medical conditions related to the central nervous system, ophthalmology, digestive system, gastrointestinal, and diabetes among others. Kanghong Pharmaceutical products include Lumitin, Bosiqing, Bolexin, Danshu, Xinluona, Yiqing, Keluoxin, Yitanning, and Xuanmaiganju. The company offers its products in the form of dispersible tablets, ophthalmic injections, oral drugs, detoxification drugs, and antiviral medicines. Kanghong Pharmaceuticals is headquartered in Chengdu, Sichuan, China.
Quick View Conbercept LOA Data
|Highest Development Stage|